.png)
MediWound
Enzymatic burn debridement (NexoBrid); BARDA mass-casualty & chemical-burn countermeasure
Vitality Radar
Pillar Analysis
Strategic Assessment
Strategic Vector
MediWound is positioned as a specialized, publicly listed enzymatic therapeutics company focused on burn care and chronic wound debridement, with an established commercial product and a late-stage pipeline candidate. Its strategy appears centered on expanding regulated, high-value medical countermeasure and wound-care applications through international commercialization and clinical development.
Efficiency Ratio
The company appears to convert a relatively modest headcount into meaningful clinical, regulatory, and commercial output, suggesting solid capital efficiency for a specialty biotech.
Evidence Signals
NexoBrid is FDA-approved for enzymatic removal of eschar in thermal burns and is marketed in the U.S., European Union, Japan, and additional international markets.
EscharEx is described as a late-stage investigational therapy for debridement of chronic wounds and is in pivotal clinical development.
The company states it has robust in-house research, development, and manufacturing capabilities for biologics in wound and burn care.
MediWound reports a full-time employee base of roughly 111 to 121 employees, indicating a small-to-mid-size operating profile.
The company’s headquarters are in Yavne, Israel, with commercial activity extending into the U.S., Europe, Japan, and other international markets.
MediWound’s portfolio includes MW005, a topically applied biological product candidate for non-melanoma skin cancers.
The company is publicly listed on Nasdaq under ticker MDWD, supporting external disclosure and market visibility.
- About
- Israeli biopharmaceutical company (HQ Yavne, Israel; Nasdaq: MDWD) specializing in enzymatic tissue-repair therapeutics. Its lead product NexoBrid is an FDA-approved orphan biologic that non-surgically removes eschar (dead tissue) from severe thermal burns in a single ~4-hour application, reducing surgical burden — a decisive advantage in mass-casualty burn events where surgical capacity is the bottleneck. Development and procurement are backed by the US BARDA under contracts valued up to $112M for mass-casualty burn preparedness (product delivered to the US stockpile via partner Vericel), plus a separate BARDA contract up to $43M to adapt NexoBrid to treat sulfur-mustard chemical-warfare skin injuries under the FDA Animal Rule. NexoBrid was deployed for burn casualties in Israel after the October 2023 attacks. Companion product EscharEx targets chronic wounds. Note: biologic/pharma (RX-BIO), outside the earlier device-only scope but among the most defense-credentialed Israeli medical companies.
- Tags
- #burns #debridement #enzymatic #masscasualty #cbrn #sulfurmustard #barda #medicalcountermeasure #rxbio #dualuse